Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Table 1 Patient demographics and clinical characteristics of the study cohort
| Characteristics | PDAC (n = 93) | Non-PDAC (n = 64) | Control (n = 88) |
| Men, n (%) | 59 (63.4) | 35 (54.7) | 38 (43.2) |
| Women, n (%) | 34 (36.6) | 29 (45.3) | 50 (56.8) |
| Age (yr) | 64 (54.74) | 54 (40.68) | 57 (43, 71) |
| CEA, n (%) | 93 (100) | 64 (100) | 82 (93.18) |
| CA19-9, n (%) | 93 (100) | 64 (100) | 69 (78.41) |
| CA125, n (%) | 93 (100) | 63 (98.44) | 42 (47.73) |
| CA242, n (%) | 93 (100) | 63 (98.33) | 0 (0.00) |
| CA724, n (%) | 93 (100) | 63 (98.44) | 0 (0.00) |
| AFP, n (%) | 93 (100) | 64 (100) | 82 (93.18) |
| Stage I, n (%) | 29 (31.18) | - | - |
| Stage II, n (%) | 22 (23.66) | - | - |
| Stage III, n (%) | 4 (4.30) | - | - |
| Stage IV, n (%) | 16 (17.20) | - | - |
| Unknown, n (%) | 22 (23.66) | - | - |
- Citation: Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer. World J Gastrointest Oncol 2024; 16(3): 659-669
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/659.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.659